KETAMINE
Additional Information
- “This is a game-changer,” says John Krystal, MD, chief psychiatrist at Yale Medicine and one of the pioneers of ketamine research in the country.
- The study “demonstrated that 100% of patients treated with ketamine demonstrated a reduction in dyskinesias (LID)”.
- Studies have shown up to a 71% response rate for ketamine administration in MDD and a up to a 64% response rate in patients with TRD.
- Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.
- SPRAVATO®, a ketamine analog developed by Johnson and Johnson for use in patients suffering from treatment-resistant depression.
DISCLAIMER
You must be 21 years old to access this website and the information contained within it. Please STOP reading and exit the site if you are under 21 years of age. By reading further, you warrant that you are 21 or older. Additionally, we do not provide or sell any drugs or plants. Attempts to sell or source drugs or plants are strictly unwelcome. F.E.M and its organizers do not condone or encourage any illegal activities, including but not limited to the use of illegal substances. This site is not a substitute for medical, psychological, or psychiatric diagnosis, treatment, or advice.